Dichlororibofuranosylbenzimidazole vs Harmaline
Mechanistic comparison of Dichlororibofuranosylbenzimidazole and Harmaline based on molecular target overlap from BindingDB and ChEMBL binding affinity data.
5
Shared Targets
15%
Jaccard Similarity
11%
IDF-Weighted Similarity
Jaccard measures raw target overlap. IDF-weighted downweights promiscuous hub targets (e.g. CYP enzymes) that bind many compounds non-specifically.
Evidence Comparison
Target Overlap
Dichlororibofuranosylbenzimidazole and Harmaline share 5 molecular targets based on binding affinity data from BindingDB (Kd/IC50 ≤ 10 µM) and ChEMBL. A Jaccard index of 0.147 means 15% of the combined target set is bound by both compounds. The IDF-weighted score of 0.114 accounts for non-specific binding to metabolic enzymes.
Note: High target overlap does not imply identical mechanism or therapeutic equivalence. Binding affinity, tissue distribution, bioavailability, and downstream signaling differ significantly between compounds even when they bind the same protein.
Frequently Asked Questions
Related Comparisons
Similar to Dichlororibofuranosylbenzimidazole
Dichlororibofuranosylbenzimidazole vs tetrabromobenzotriazole2 targetsDichlororibofuranosylbenzimidazole vs Aminocaproic2 targetsDichlororibofuranosylbenzimidazole vs Dinitrochlorobenzene6 targetsDichlororibofuranosylbenzimidazole vs Desoxycorticosterone4 targetsDichlororibofuranosylbenzimidazole vs quinalizarin2 targets